The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Self-citationAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Research works printed but not linked: 41
- Holst JJ (2002) Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18:430–441 · DOI
- Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ (1995) Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126–1131 · DOI · Paper page
- Holst JJ, Deacon CF (1998) Inhibition of the activity of dipeptidyl peptidase IV activity as a treatment for type 2 diabetes. Diabetes 47:1663–1670 · DOI · Paper page
- Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O (1994) Structure-activity studies of glucagon-like peptide-1. J Biol Chem 269:6275–6278 · DOI · Paper page
- Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li, X (1999) Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324–1331 · DOI · Paper page
- Deacon CF, Hughes TE, Holst JJ (1998) Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in anesthetized pigs. Diabetes 47:764–769 · DOI · Paper page
- Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ (2002) Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172:355–362 · DOI
- Marguet D, Baggio L, Kobayashi T et al (2000) Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 97:6874–6879 · DOI · Paper page
- Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU (1998) Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47:1253–1258 · DOI · Paper page
- Pospisilik JA, Stafford SG, Demuth HU et al (2002) Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51:943–950 · DOI · Paper page
- Sudre B, Broqua P, White RB et al (2002) Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 51:1461–1469 · DOI · Paper page
- Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078–2084 · DOI · Paper page
- Ahrén B, Simonsson E, Larsson H et al (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869–875 · DOI · Paper page
- Turner AJ, Isaac RE, Coates D (2001) The neprilysin (NEP) family of zinc metallopeptidases: genomics and function. Bioessays 23:261–269 · DOI · Paper page
- Hupe-Sodmann K, Göke R, Göke B et al (1997) Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells. Peptides 18:625–632 · DOI
- Hupe-Sodmann K, McGregor GP, Bridenbaugh R et al (1995) Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149–156 · DOI · Paper page
- Northridge DB, Jardine AG, Alabaster CT et al (1989) Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet 2:591–593 · DOI · Paper page
- Kaye B, Brearley CJ, Cussans NJ, Herron M, Humphrey MJ, Mollatt AR (1997) Formation and kinetics of the active drug candoxatrilat in mouse, rabbit, dog and man following administration of the prodrug candoxatril. Xenobiotica 27:1091–1102 · DOI
- Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ (2001) Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and anti-hyperglycemic effects in anesthetized pigs. Diabetes 50:1588–1597 · DOI
- Trebbien R, Klarskov L, Olesen M, Holst JJ, Carr RD, Deacon CF (2004) Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. Am J Physiol Endocrinol Metab 287:E431–E438 · DOI
- Plamboeck A, Holst JJ, Carr RD, Deacon CF (2002) Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo. In: Hildebrandt M, Klapp B, Hoffman T, Demuth HU (eds) Dipeptidyl aminopeptidases in health and disease: advances in experimental medicine and biology, vol 524. Kluwer Academic/Plenum, NY, pp 303–312
- Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon-like peptide-1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271:E458–E464
- Ørskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535–539 · DOI · Paper page
- Ørskov C, Jeppesen J, Madsbad S, Holst JJ (1991) Proglucagon products in the plasma of non-insulin dependent diabetics and nondiabetic controls in the fasting state and following oral glucose and intravenous arginine. J Clin Invest 87:415–423 · DOI · Paper page
- Selmeci L, Szokodi I, Horvat-Karajz K (1996) A sensitive microplate-based continuous-monitoring (kinetic) assay for serum neutral endopeptidase (EC 3.4.24.11) activity. Clin Chim Acta 244:111–116 · doi:10.1016/0009-8981(95)06194-0
- Danilewicz JC, Barclay PL, Barnish IT et al (1989) UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem Biophys Res Commun 164:58–65 · doi:10.1016/0006-291x(89)91682-3
- Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A (1993) Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87–146
- Northridge DB, Currie PF, Newby DE et al (1999) Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail 1:67–72 · doi:10.1016/s1388-9842(98)00003-8
- Yoshida K, Kanazawa M, Casley DJ, Katopothis A, Johnston CI (1998) Inhibition of kidney neutral endopeptidase after administration of the neutral endopeptidase inhibitor candoxatril: quantitation by autoradiography. J Cardiovasc Pharmacol 32:702–708 · doi:10.1097/00005344-199811000-00004
- Hansen L, Deacon CF, Orskov C, Holst JJ (1999) Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356–5363 · DOI · Paper page
- Fulcher IS, Matsas R, Turner AJ, Kenny AJ (1982) Kidney neutral endopeptidase and the hydrolysis of enkephalin by synaptic membranes show similar sensitivity to inhibitors. Biochem J 203:519–522 · DOI · Paper page
- Chipkin RE, Kreutner W, Billard W (1984) Potentiation of the hypoglycemic effect of insulin by thiorphan, an enkephalinase inhibitor. Eur J Pharmacol 102:151–154 · doi:10.1016/0014-2999(84)90349-2
- Blais C Jr, Fortin D, Rouleau JL, Molinaro G, Adam A (2000) Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts. J Pharmacol Exp Ther 295:621–626
- Arbin V, Claperon N, Fournié-Zaluski M-C, Roques BP, Peyroux J (2001) Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanapril on insulin sensitivity in obese Zucker rat. Br J Pharmacol 133:495–502 · DOI
- Arbin V, Claperon N, Fournié-Zaluski M-C, Roques BP, Peyroux J (2003) Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanapril on insulin sensitivity in lean and obese Zucker rats. J Cardiovasc Pharmacol 41:254–264 · DOI
- Russell JC, Kelly SE, Schäfer S (2004) Vasopeptidase inhibition improves insulin sensitivity and endothelial function in the JCR:LA-cp rat. J Cardiovasc Pharmacol 44:258–265 · DOI
- Wang CH, Leung N, Lapointe N et al (2003) Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats. Circulation 107:1923–1929 · DOI
- Schäfer S, Linz W, Bube A et al (2003) Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats. Cardiovasc Res 60:447–454 · DOI
- Lin MC, Wright DE, Hruby VJ, Rodbell M (1975) Structure–function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn-28, Thr-29)(homoserine lactone-27)-glucagon. Biochemistry 14:1559–1563 · DOI
- Deacon CF, Ahrén B, Holst JJ (2004) Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 13:1091–1102 · DOI · Paper page
- Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609–613 · DOI · Paper page
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationKootte, R. S., Levin, E., Salojärvi, J., Smits, L. P., Hartstra, A. V., Udayappan, S. D., Hermes, G., Bouter, K. E., Koopen, A. M., Holst, J. J., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.008 · Cited by 1,039
Self-citationThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Metadata
- Authors
- Plamboeck, A., Holst, J. J., Carr, R. D., & Deacon, C. F.
- Venue
- Diabetologia
- Published
- 2005-07-16
- Volume
- 48
- Issue
- 9
- Pages
- 1882-1890
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2079355745
- Cited by
- 173
- References
- 4
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. https://app.cochat.ai/papers/10.1007/s00125-005-1847-7
- The paper
- Plamboeck, A., Holst, J. J., Carr, R. D., & Deacon, C. F. (2005). Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. https://doi.org/10.1007/s00125-005-1847-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.